Clarity Pharmaceuticals Ltd Total Assets
Clarity Pharmaceuticals Ltd total assets. Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) holds total assets worth AU$199.06 Million AUD (≈ $140.85 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Clarity Pharmaceuticals Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Clarity Pharmaceuticals Ltd (2018–2026)
Total assets of Clarity Pharmaceuticals Ltd from 2018 to 2026. This chart illustrates how Clarity Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See Clarity Pharmaceuticals Ltd share price for real-time trading data and today's change.
Clarity Pharmaceuticals Ltd - Asset Composition Analysis
Clarity Pharmaceuticals Ltd Total Assets Breakdown (June 2026)
Clarity Pharmaceuticals Ltd total assets breakdown as of June 2026. Clarity Pharmaceuticals Ltd's total assets of AU$199.06 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 89.6% |
| Accounts Receivable | AU$12.82 Million | 6.4% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2018–2026)
This chart illustrates how Clarity Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Clarity Pharmaceuticals Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clarity Pharmaceuticals Ltd's current assets represent 99.7% of total assets in 2026, an increase from 97.8% in 2018.
- Cash Position: Cash and equivalents constituted 89.6% of total assets in 2026, up from 60.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 6.4% of total assets.
Clarity Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Clarity Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Clarity Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.09 | 9.69 | 10.00 |
| Quick Ratio | 16.09 | 9.69 | 10.00 |
| Cash Ratio | 0.00 | 2.83 | 0.00 |
| Working Capital | AU$186.15 Million | AU$90.23 Million | AU$20.26 Million |
Clarity Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Clarity Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.43 |
| Latest Market Cap to Assets Ratio | 1.83 |
| Asset Growth Rate (YoY) | 96.8% |
| Total Assets | AU$199.06 Million |
| Market Capitalization | $364.29 Million USD |
Valuation Analysis
Above Book Valuation: The market values Clarity Pharmaceuticals Ltd's assets above their book value (1.83x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Clarity Pharmaceuticals Ltd's assets grew by 96.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Clarity Pharmaceuticals Ltd (2018–2026)
The table below shows the annual total assets of Clarity Pharmaceuticals Ltd from 2018 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | AU$199.06 Million ≈ $140.85 Million |
+96.76% |
| 2025-06-30 | AU$101.17 Million ≈ $71.59 Million |
-34.57% |
| 2024-06-30 | AU$154.63 Million ≈ $109.41 Million |
+101.09% |
| 2023-06-30 | AU$76.90 Million ≈ $54.41 Million |
-22.97% |
| 2022-06-30 | AU$99.82 Million ≈ $70.63 Million |
+341.44% |
| 2021-06-30 | AU$22.61 Million ≈ $16.00 Million |
+148.08% |
| 2020-06-30 | AU$9.12 Million ≈ $6.45 Million |
-12.04% |
| 2019-06-30 | AU$10.36 Million ≈ $7.33 Million |
+271.88% |
| 2018-06-30 | AU$2.79 Million ≈ $1.97 Million |
-- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic rad… Read more